Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1670 studies found for:    rituximab
Show Display Options
Rank Status Study
1 Withdrawn Rituximab for GVHD
Conditions: Graft vs Host Disease;   Alogenic Hematopoietic Transplant
Intervention: Drug: Rituximab
2 Completed Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
Conditions: Renal Transplant;   Autoimmune Diseases
Interventions: Drug: Rituximab 375;   Drug: rituximab 1000
3 Active, not recruiting Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Interventions: Drug: lenalidomide-low dose dexamethasone plus rituximab;   Drug: Lenalidomide + Rituximab
4 Terminated
Has Results
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
Conditions: Leukemia;   Acute Lymphoblastic Leukemia;   ALL
Intervention: Drug: rituximab
5 Active, not recruiting Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus
Condition: Pemphigus Disease
Interventions: Drug: General Corticotherapy;   Drug: Rituximab
6 Recruiting Intrathecal Rituximab in Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Nervous System Diseases
Interventions: Drug: Rituximab IT;   Drug: methylprednisolone IV;   Drug: Rituximab IV
7 Active, not recruiting Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Condition: Lymphoma
Interventions: Drug: Fludarabine;   Drug: Novantrone;   Drug: Decadron;   Drug: Rituximab;   Drug: Interferon;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bleomycin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Ara-C;   Drug: Methyl-Prednisolone;   Drug: Procarbazine;   Drug: Prednisone
8 Recruiting A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum
9 Completed
Has Results
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Conditions: Anemia, Aplastic;   Red-Cell Aplasia, Pure;   Anemia, Diamond-Blackfan
Intervention: Drug: Rituximab
10 Completed
Has Results
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Condition: Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);   Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);   Drug: Bendamustine;   Drug: Rituximab
11 Active, not recruiting A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab - CHOP;   Drug: Rituximab - CVP;   Drug: Rituximab - Bendamustine
12 Active, not recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Conditions: Follicular Lymphoma;   B-cell Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Ibrutinib;   Drug: rituximab
13 Recruiting A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Rituximab;   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin
14 Terminated Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
Conditions: Grafting;   Renal Transplantation;   Transplantation, Kidney;   Chronic Allograft Nephropathy
Intervention: Drug: MabThera
15 Completed Rituximab to Treat Stiff Person Syndrome
Condition: Stiff Person Syndrome
Interventions: Drug: Rituximab;   Drug: rituximab or placebo
16 Active, not recruiting Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
Conditions: Leukemia;   Lymphoid Malignancies;   Metastatic Malignant Neoplasm to the Leptomeninges
Intervention: Drug: Intrathecal Rituximab
17 Recruiting Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
Condition: Prostate Cancer
Intervention: Drug: rituximab
18 Unknown  Rituximab Trial for Pediatric Nephrotic Syndrome
Conditions: Steroid Resistant Nephrotic Syndrome;   Steroid Dependent Nephrotic Syndrome
Interventions: Drug: Rituximab;   Drug: Placebo
19 Withdrawn Alemtuzumab and Rituximab in Aplastic Anemia
Condition: Aplastic Anemia
Intervention: Drug: Alemtuzumab and Rituximab
20 Active, not recruiting A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: LBH589;   Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years